JNK

SX 011 is a p38α inhibitor.

JNK3 inhibitor, potent and selective

BSJ-04-122: MKK4/7 inhibitor with IC50s of 4 nM & 181 nM, used in cancer research.

GSK649A is a novel activator of Satellite Cell Proliferation, it could enhance repair of Damaged Muscle.

JNK3 inhibitor-4: potent, selective JNK3 blocker (IC50=1.0nM), neuroprotective, BBB-permeable.

J30-8 is a JNK3 inhibitor (IC50: 40 nM) with neuroprotective activity and can be used to study neurodegenerative diseases such as Alzheimer's disease.

ZG-10 (JNK-IN-2) is an inhibitor of JNK, blocking JNK1, JNK2, and JNK3, and is used in studies of SARS-CoV-2 virus infection.

JNK-1-IN-1 is an inhibitor specifically targeting JNK-1, also exhibiting inhibition of MKK7 with an IC50 value of 7.8μM.

JNK-IN-11 inhibits JNK1/2/3 (IC50: 2.2/21.4/1.8 μM); promising for Alzheimer's/Parkinson's research.

JNK3 inhibitor-1: potent, selective, IC50 of 0.005 μM, orally bioavailable, brain-penetrant.

JNK3 Inhibitor-3 selectively blocks JNK3 (>4.1 nM), crosses the blood-brain barrier, is orally active, and improves memory in dementia mice.

Ezatiostat HCl (TLK199) inhibits glutathione S-transferase, GSTP1-1 specifically, and may treat cytopenias.

TC ASK 10 is a potent, selective and orally active inhibitor of apoptosis signal-regulating kinase 1 (ASK1,IC50 = 14 nM). The IC50 value for ASK2 is 0.51 μM.

JAK3-IN-13: Oral JAK3 inhibitor, selective & potent. Acts on NK1, JNK2, JNK3, Tyk2. Anti-tumor. IC50: JNK3, 8 nM; Tyk2, 365 nM; JNK2, 2039 nM; NK1, 4728 nM.

p38 Kinase inhibitor 8 (Compound CCLXXVIII) is an orally active inhibitor targeting p38β and JNK2α2, with IC50 values of 6.3 nM and 53.6 nM, respectively. It has demonstrated anti-inflammatory effects in a rat model of collagen-induced arthritis.

JNK-IN-23 (Compound K12) is an inhibitor of JNK. It effectively inhibits the proliferation of MDA-MB-231 cells with a GIC50 of 30 nM. In vivo, JNK-IN-23 blocks metastatic growth of triple-negative breast cancer (TNBC). Additionally, it suppresses the growth of lung metastases by dual targeting of glutaminase-1 (GLS) and the pyruvate dehydrogenase complex (PDHC).

Nitric oxide production-IN-11k is a compound that inhibits TLR4, JNK, and NF-κB signaling pathways. It suppresses nitric oxide (NO) production in LPS-stimulated RAW264.7 cells, with an IC₅₀ of 23.2 µM. By downregulating TLR4 expression and reducing the phosphorylation level of JNK, Nitric oxide production-IN-11k inhibits the activation of NF-κB, thereby blocking the transcription of inflammation-related genes. This leads to decreased expression of iNOS and COX-2, and consequently reduces the production of inflammatory mediators such as NO, PGE₂, and TNF-α, exerting anti-inflammatory effects. Nitric oxide production-IN-11k shows potential application value in the study of rheumatoid arthritis and other inflammatory diseases.

JNK-1-IN-5 (Compound 14) is a potent JNK1 inhibitor with sub-nanomolar efficacy. It effectively inhibits TGF-β-induced epithelial-mesenchymal transition and shows promise for research targeting JNK1 as an anti-pulmonary fibrosis agent.

PT109 is a multikinase inhibitor that targets JNK and other kinases, playing a crucial role in anti-inflammatory, antioxidative, neurogenic, and synaptogenic processes. Specifically, PT109 inhibits JNK isoforms with the following IC50 values: JNK1 at 0.143 μM, JNK2 at 0.831 μM, and JNK3 at 0.285 μM. It also inhibits SGK isoforms (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM) and ROCK2 (IC50=34 μM). Additionally, PT109 reprograms polymorphic glioblastoma multiforme (GBM) into oligodendroglia via the PTBP1/PKM1/2 pathway and alters the metabolic pattern of GBM to exhibit antiglioma activity.

JD123 inhibits the activity of JNK1 and the expression of cJun (1-135). It is an ATP-competitive inhibitor specific to p38-γ MAPK and has no effect on ERK1, ERK2, p38-α, p38-β, and p38-δ.